miR-149 controls non-alcoholic fatty liver by targeting FGF-21

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 8, 2016, Pages 1603-1608

  Xiao, Junjie ^a   Lv, Dongchao ^a   Zhao, Yingying ^b   Chen, Xiaoyu ^b   Song, Meiyi ^b   Liu, Jingqi ^b   Bei, Yihua ^a   Wang, Fei ^b   Yang, Wenzhuo ^b   Yang, Changqing ^b  

^a SHANGHAI UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

fibroblast growth factor 21; miR 149; Non alcoholic fatty liver disease

Indexed keywords

FAT DROPLET; FIBROBLAST GROWTH FACTOR 21; LONG CHAIN FATTY ACID; MICRORNA; MICRORNA 149; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE TARGETING; GENETIC TRANSFECTION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIPID DIET; LIPOGENESIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84979059401     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12848     Document Type: Article

References (30)

1. Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract. 2011; 26: 565–76.
2. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010; 51: 1820–32.
3. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Digest Dis Sci. 2010; 55: 560–78.
4. Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of D-adenosylmethionine. Exp Biol Med. 2015; 240: 809–20.
5. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. Can Med Assoc J. 2005; 172: 899–905.
6. Grant LM, Lisker-Melman M. Nonalcoholic fatty liver disease. Ann Hepatol. 2004; 3: 93–9.
7. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002; 122: 1649–57.
8. Sayed D, Abdellatif M. Micrornas in development and disease. Physiol Rev. 2011; 91: 827–87.
9. Kim VN, Han J, Siomi MC. Biogenesis of small rnas in animals. Nat Rev Mol Cell Bio. 2009; 10: 126–39.
10. Carthew RW, Sontheimer EJ. Origins and mechanisms of mirnas and sirnas. Cell. 2009; 136: 642–55.
11. Xiao J, Liang D, Zhang H, et al. MicroRNA-204 is required for differentiation of human-derived cardiomyocyte progenitor cells. J Mol Cell Cardiol. 2012; 53: 751–9.
12. Yamada H, Ohashi K, Suzuki K, et al. Longitudinal study of circulating mir-122 in a rat model of non-alcoholic fatty liver disease. Clin Chim Acta. 2015; 446: 267–71.
13. Hur W, Lee JH, Kim SW, et al. Downregulation of microrna-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the ampk/akt pathway. Int J Biochem Cell B. 2015; 64: 265–76.
14. Ceccarelli S, Panera N, Gnani D, et al. Dual role of microRNAs in NAFLD. Int J Mol Sci. 2013; 14: 8437–55.
15. Panera N, Gnani D, Crudele A, et al. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease. World J Gastroenterol. 2014; 20: 15079–86.
16. Xiao J, Bei Y, Liu J, et al. miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21. J Cell Mol Med. 2016; 2: 204–16.
17. Berlanga A, Guiu-Jurado E, Porras JA, et al. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp gastroenterol. 2014; 7: 221–39.
18. Vos MB. Nutrition, nonalcoholic fatty liver disease and the microbiome: recent progress in the field. Curr Opin Lipidol. 2014; 25: 61–6.
19. Olaywi M, Bhatia T, Anand S, et al. Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. Hbpd Int. 2013; 12: 584–8.
20. Wang Y, Zheng X, Zhang Z, et al. MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer. PLoS ONE. 2012; 7: e41693.
21. Oster B, Linnet L, Christensen LL, et al. Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer. Int J Cancer. 2013; 132: 2303–15.
22. Wang F, Ma YL, Zhang P, et al. SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer. J Pathol. 2013; 229: 12–24.
23. Ding SL, Wang JX, Jiao J, et al. A pre-microRNA-149 (miR-149) genetic variation affects miR-149 maturation and its ability to regulate the Puma protein in apoptosis. J Biol Chem. 2013; 288: 26865–77.
24. Zhang MW, Jin MJ, Yu YX, et al. Associations of lifestyle-related factors, hsa-miR-149 and hsa-miR-605 gene polymorphisms with gastrointestinal cancer risk. Mol Carcinog. 2012; 51: E21–31.
25. Jeon YJ, Kim OJ, Kim SY, et al. Association of the miR-146a, miR-149, miR-196a2, and miR-499 polymorphisms with ischemic stroke and silent brain infarction Risk. Arterioscler Thromb Vasc Biol. 2013; 33: 420–30.
26. Chamorro-Jorganes A, Araldi E, Rotllan N, et al. Autoregulation of glypican-1 by intronic microRNA-149 fine tunes the angiogenic response to FGF2 in human endothelial cells. J Cell Sci. 2014; 127: 1169–78.
27. Mohamed JS, Hajira A, Pardo PS, et al. MicroRNA-149 inhibits PARP-2 and promotes mitochondrial biogenesis via SIRT-1/PGC-1α network in skeletal muscle. Diabetes. 2014; 63: 1546–59.
28. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8: 235–53.
29. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005; 115: 1627–35.
30. Murata Y, Konishi M, Itoh N. FGF21 as an endocrine regulator in lipid metabolism: from molecular evolution to physiology and pathophysiology. J Nutr Metab. 2011; 2011: 981315.